about
Guidance molecules in lung cancerA novel vascular disrupting agent plinabulin triggers JNK-mediated apoptosis and inhibits angiogenesis in multiple myeloma cellsThe neurotrophic receptor Ntrk2 directs lymphoid tissue neovascularization during Leishmania donovani infectionThe alternative splicing factor Nova2 regulates vascular development and lumen formation.Computational Model for Tumor Oxygenation Applied to Clinical Data on Breast Tumor Hemoglobin Concentrations Suggests Vascular Dilatation and CompressionNovel surface targets and serum biomarkers from the ovarian cancer vasculatureAntibody drug-conjugates targeting the tumor vasculature: Current and future developmentsIdentification of thioaptamer ligand against E-selectin: potential application for inflamed vasculature targetingIdentification of novel vascular markers through gene expression profiling of tumor-derived endothelium.Slit2/Robo4 signaling modulates HIV-1 gp120-induced lymphatic hyperpermeability.Selective delivery of therapeutic agents for the diagnosis and treatment of cancer.Expression of angiostatin cDNA in human gallbladder carcinoma cell line GBC-SD and its effect on endothelial proliferation and growth.Heating as a rapid purification method for recovering correctly-folded thermotolerant VH and VHH domains.Towards a ligand targeted enzyme prodrug therapy: single round panning of a beta-lactamase scaffold library on human cancer cells.Identification of accessible human cancer biomarkers using ex vivo chemical proteomic strategies.A novel method of differential gene expression analysis using multiple cDNA libraries applied to the identification of tumour endothelial genes.Mouse thymus targeted peptide isolated by in vivo phage display can inhibit bioactivity of thymus output in vivo.Bone marrow multipotent mesenchymal stroma cells act as pericyte-like migratory vehicles in experimental gliomasNovel beta-lactamase-random peptide fusion libraries for phage display selection of cancer cell-targeting agents suitable for enzyme prodrug therapyNon-redundant role for IL-12 and IL-27 in modulating Th2 polarization of carcinoembryonic antigen specific CD4 T cells from pancreatic cancer patientsAlternative splicing of the angiogenesis associated extra-domain B of fibronectin regulates the accessibility of the B-C loop of the type III repeat 8.Cancer cell-specific internalizing ligands from phage displayed beta-lactamase-peptide fusion libraries.A combinatorial approach for targeted delivery using small molecules and reversible masking to bypass nonspecific uptake in vivoExpression, engineering and characterization of the tumor-targeting heterodimeric immunocytokine F8-IL12.An integrated approach for the rational design of nanovectors for biomedical imaging and therapy.Lymphoma endothelium preferentially expresses Tim-3 and facilitates the progression of lymphoma by mediating immune evasion.Synthesis and in vitro evaluation of cyclic NGR peptide targeted thermally sensitive liposome.Adenoviral targeting of gene expression to tumors.A novel synthetic naïve human antibody library allows the isolation of antibodies against a new epitope of oncofetal fibronectin.Tumor vasculature targeting: a generally applicable approach for functionalized nanomaterials.Selective targeted delivery of the TNF-alpha receptor p75 and uteroglobin to the vasculature of inflamed tissues: a preliminary report.Periostin expression and epithelial-mesenchymal transition in cancer: a review and an update.Combination of temozolomide with immunocytokine F16-IL2 for the treatment of glioblastoma.Development, optimization, and validation of novel anti-TEM1/CD248 affinity agent for optical imaging in cancerOvercoming key technological challenges in using mass spectrometry for mapping cell surfaces in tissues.Antitumor agent calixarene 0118 targets human galectin-1 as an allosteric inhibitor of carbohydrate bindingA chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels.A perspective on vascular disrupting agents that interact with tubulin: preclinical tumor imaging and biological assessmentProteasome activator complex PA28 identified as an accessible target in prostate cancer by in vivo selection of human antibodies.Identification and characterization of angiogenesis targets through proteomic profiling of endothelial cells in human cancer tissues.
P2860
Q24598659-285FE1D4-B169-49F3-8203-3E4107D0F5E1Q24622083-55CD987D-ADB5-47A4-98A0-45308281EDA5Q27321179-A2AE6E8A-8DCC-4CCA-9D8E-505F80D898D5Q27321847-FFFA9568-DD6A-48F9-86E2-B09A47A48DF0Q27327081-C5C7F9E3-23DC-4810-AEC6-B57B7626AD47Q28238739-CB766009-1F23-41FF-8690-8EE329F989AFQ28270261-C69ED745-8739-4262-B71E-066ED231ECB7Q28475666-82112DDD-CDC3-48AF-AEF8-D2FE181F5D2EQ30843102-DA1A3B9C-DDA4-4DDA-A9C5-76D883D7D1ADQ31044936-DC21DBBD-19D2-498D-B404-69786A78751AQ33230098-6D749497-C216-4141-972C-B8FBCAC49360Q33244333-BA4EA8C2-1D0F-43BF-864F-1BA5FA276856Q33270541-05696E1D-CA72-4F9F-864E-3B58729FE2DCQ33272567-C365E30B-ED88-48C3-BAE9-151B39FB4B44Q33309341-A256B627-AECD-491F-A4A0-273BAF6F46BBQ33327177-4EEBFFED-BE5A-4DF4-B6B9-66569E916325Q33382036-EB8D373A-6ADD-4E49-87F7-FA0C098F1AC6Q33382708-0F452ECD-D5FF-4C6A-8476-28BA322395C7Q33502835-1BD63997-75B6-4A19-B687-BAC55E428590Q33508227-4F593CC2-7BDA-43B2-B74D-41797AADA819Q33531787-833BE149-20F8-4AEE-8BE5-FCFF3ECF9408Q33539508-535D4DB6-3C83-43DE-AFE7-AAB9FFF8169FQ33576606-05C39429-68C3-46AD-843E-0888790B528DQ33605532-3A5884E8-E62C-4A36-AFB3-24476C18801FQ33679533-9B9B3AA0-1678-4AD1-82A3-0AF38AE8CCFBQ33730111-5AA8181C-B330-4913-958B-7ED7FE8B0414Q33762115-C3C1737B-D78F-475A-89EE-1183C183B181Q33862714-C3346B0B-378B-45A3-9957-3E4B9F6A85D0Q33870905-B0C98178-9738-45C7-A9A7-93BFE76CA6F7Q34019838-1757670C-2F78-4DF9-8DB8-25B1DB901C5FQ34072266-FDE321C1-0C48-4CD2-9412-BFD271E8C948Q34224075-A96E4C2C-F6E3-4CE5-A232-12B99E26AA57Q34253705-5F7100CD-196D-4FEB-BE97-153098601A16Q34334475-AC5CC6C1-4C6A-41CE-9D6E-5D81FF451DBEQ34551892-276CD4AC-D536-406A-8CA3-2AED09BD5419Q34564173-27D8C9A0-12D5-4DFE-B2F0-310D9525486EQ34746019-6EDB1C42-E66D-4D6F-951E-FE990448ADCCQ34765364-06F84DCF-B49C-4A05-A42A-B7954C939ED1Q34897576-4BDAAEF2-0B4C-4932-BCBE-9CCBEA4DD250Q35043619-17F18705-DF6B-43D1-97C7-446567F0A603
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Tumour vascular targeting.
@ast
Tumour vascular targeting.
@en
type
label
Tumour vascular targeting.
@ast
Tumour vascular targeting.
@en
prefLabel
Tumour vascular targeting.
@ast
Tumour vascular targeting.
@en
P356
P1476
Tumour vascular targeting.
@en
P2093
Roy Bicknell
P2888
P304
P356
10.1038/NRC1627
P407
P50
P577
2005-06-01T00:00:00Z